ARCHIVES

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Unclear Whether Insurance Will Cover AACR Losses

April 25, 2003

Grantees Not In Danger Of Losing Cost-Free Biological Materials, But Can’t Have Chemicals

September 9, 1977

Senate Confirms FDA Commissioner Von Eschenbach.

December 8, 2006

Self-Collected Pap Smear Tests Could Advance HPV Screening

January 27, 2012

Golde To Step Down As Physician-in-Chief At Memorial Sloan-Kettering Next Year.

January 26, 2001

Mass. Congressman Pressed For $1.5 M Proton Beam Funds

August 18, 1989